Phase III study of TLC D-99 (liposome encapsulated doxorubicin) vs. free doxorubicin (DOX) in patients with metastatic breast cancer (MBC)

被引：0
|
作者：
Winer, E
Batist, G
Harris, L
Hooftman, L
Park, Y
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Liposome Co, Princeton, NJ USA
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
59O
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [31] A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study
    Philippe A. Cassier
    Sylvie Chabaud
    Véronique Trillet-Lenoir
    Pierre-Yves Peaud
    Jean-Dominique Tigaud
    Hervé Cure
    Hubert Orfeuvre
    Bruno Salles
    Claude Martin
    Jean-Philippe Jacquin
    Cecile Agostini
    Jean-Paul Guastalla
    David Pérol
    Thomas Bachelot
    Breast Cancer Research and Treatment, 2008, 109 : 343 - 350
  • [32] Phase II study of taxotere(R) (docetaxel, D), Doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in the treatment of metastatic breast cancer (MBC)
    Nabholtz, JM
    Mackey, JR
    Smylie, M
    Paterson, A
    Noel, D
    AlTweigeri, T
    Delorme, F
    BREAST, 1997, 6 (05): : P953 - P953
  • [33] Population pharmacokinetics and toxicity correlation analysis of free and liposome-encapsulated doxorubicin in Chinese patients with advanced breast cancer
    Gaoqi Xu
    Dihong Yang
    Chaoneng He
    Like Zhong
    Junfeng Zhu
    Qi Shu
    Haiying Ding
    Wenxiu Xin
    Yinghui Tong
    Xiao Zhu
    Luo Fang
    Cancer Chemotherapy and Pharmacology, 2023, 92 : 181 - 192
  • [34] ANTITUMOR-ACTIVITY OF LIPOSOME-ENCAPSULATED DOXORUBICIN IN ADVANCED BREAST-CANCER - PHASE-II STUDY
    TREAT, J
    GREENSPAN, A
    FORST, D
    SANCHEZ, JA
    FERRANS, VJ
    POTKUL, LA
    WOOLLEY, PV
    RAHMAN, A
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (21) : 1706 - 1710
  • [35] Final results of a phase II study of Taxotere (docetaxel, D), doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in the treatment of metastatic breast cancer (MBC)
    Nabholtz, JM
    Mackey, JR
    Smylie, M
    Paterson, A
    Noel, D
    Al-Twelgeri, T
    Janowska-Wieczorek, A
    Delome, F
    Riva, A
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S43 - S43
  • [36] Taxotere® (T) and doxorubicin (D) combination:: A phase II South American study in first line treatment (tt) of metastatic breast cancer (MBC)
    Vallejos, C
    Nunez, P
    Orlandi, L
    Carranza, H
    Fodor, M
    Reyes, JM
    Majlis, A
    Gavilanes, P
    Boussard, B
    Salas, E
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S329 - S329
  • [37] Cardiac toxicity in a phase III study of doxorubicin (DOX) and bevacizumab (BEV) for patients (pts) with metastatic soft-tissue sarcomas
    D'Adamo, DR
    Anderson, S
    Albritton, K
    Yamada, J
    Riedel, E
    Scheu, K
    Schwartz, GK
    Chen, H
    Maki, RG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 821S - 821S
  • [38] Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer
    Holmes, FA
    Madden, T
    Newman, RA
    Valero, V
    Theriault, RL
    Fraschini, G
    Walters, RS
    Booser, DJ
    Buzdar, AU
    Willey, J
    Hortobagyi, GN
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) : 2713 - 2721
  • [39] DOCETAXEL IN COMBINATION WITH NON PEGYLATED LIPOSOMEEN CAPSULATED DOXORUBICIN (MYOCET) FOR THE TREATMENT OF METASTATIC BREAST CANCER (MBC) PATIENTS: A PHASE II CLINICAL STUDY
    Cutuli, Irene
    Orizzonte, Giovanna
    Condemi, Giovanni
    ANNALS OF ONCOLOGY, 2009, 20
  • [40] Bi-weekly administration of pegylated liposomal doxorubicin plus paclitaxel in metastatic breast cancer (MBC) patients: A phase II study.
    Simoncini, E
    Ferrari, VD
    Amoroso, V
    Valcamonico, F
    Grisanti, S
    Vassalli, L
    Marpicati, P
    Montini, E
    Rangoni, G
    Marini, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 88S - 88S
12345